See the DrugPatentWatch profile for tigecycline

Based on the information provided, there is some evidence to suggest that certain patient populations may be more susceptible to transaminase changes when treated with the antibiotic tigecycline. However, it is important to note that the data on this topic is not extensive, and more research is needed to fully understand the relationship between tigecycline and transaminase changes in specific patient populations.

Transaminases, also known as aminotransferases, are enzymes found in the liver that help to metabolize proteins. When the liver is damaged or inflamed, transaminase levels in the blood can increase. Therefore, monitoring transaminase levels is a common way to assess liver function in patients taking medications that can affect the liver.

Tigecycline is a broad-spectrum antibiotic that is used to treat a variety of bacterial infections, including skin and soft tissue infections, intra-abdominal infections, and community-acquired pneumonia. Like many antibiotics, tigecycline can cause liver enzyme elevations, including transaminase changes. However, it is unclear whether certain patient populations are more susceptible to these changes than others.

One study published in the Journal of Antimicrobial Chemotherapy in 2012 investigated the relationship between tigecycline and transaminase changes in patients with severe sepsis or septic shock [1]. The study found that transaminase levels increased in a significant proportion of patients treated with tigecycline, particularly in those with baseline transaminase elevations. However, the study did not find any significant differences in transaminase changes between tigecycline and comparator groups.

Another study published in the Journal of Clinical Pharmacy and Therapeutics in 2013 examined the safety and efficacy of tigecycline in patients with renal impairment [2]. The study found that tigecycline was generally well-tolerated in patients with renal impairment, but noted that transaminase changes were more common in these patients than in those with normal renal function.

Overall, while there is some evidence to suggest that certain patient populations, such as those with severe sepsis or septic shock or renal impairment, may be more susceptible to transaminase changes when treated with tigecycline, more research is needed to confirm these findings. Healthcare providers should continue to monitor liver function in all patients taking tigecycline, particularly those in high-risk populations.

Sources:

1. <https://academic.oup.com/jac/article/67/11/2651/846899>
2. <https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.12053>
3. DrugPatentWatch.com - Tigecycline (Accessed on March 15, 2023) <https://www.drugpatentwatch.com/drugs/tigecycline>